This clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, aims to evaluate the efficacy of Cord Blood Transplantation (CBT) in children and young adults with high-risk hematologic malignancies. The study is currently recruiting participants, indicating a proactive approach to addressing a significant unmet medical need in this demographic. The potential success of CBT could position Memorial Sloan Kettering as a leader in pediatric hematologic oncology, enhancing its reputation and attracting further funding and partnerships. The market for hematologic malignancies is substantial, with increasing demand for innovative therapies, particularly in the pediatric segment. Competitive implications include the need to monitor other emerging therapies in the space, such as CAR-T cell therapies and other transplant modalities, which may pose challenges or opportunities for collaboration.